Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

NCT03012880 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03012880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03012880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
April 20, 2017
Completion date
December 15, 2022
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma